Bolt Biotherapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Bolt Biotherapeutics Current Ratio Growth & History (BOLT)
Bolt Biotherapeutics's current ratio was 3.59 for fiscal 2025.
View full Bolt Biotherapeutics company overviewBolt Biotherapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.59 | 0.38 | +11.94% |
| 2024 | 2024-12-31 | 3.20 | −1.96 | −37.98% |
| 2023 | 2023-12-31 | 5.17 | −2.30 | −30.84% |
| 2022 | 2022-12-31 | 7.47 | −1.40 | −15.75% |
| 2021 | 2021-12-31 | 8.87 | 6.62 | +293.92% |
| 2020 | 2020-12-31 | 2.25 | — | — |
Bolt Biotherapeutics quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.61 | −0.50 | −16.06% |
| Q1 2026 | 2026-03-31 | 3.51 | 0.37 | +11.89% |
| Q4 2025 | 2025-12-31 | 3.59 | 0.38 | +11.94% |
| Q3 2025 | 2025-09-30 | 3.57 | 0.41 | +13.05% |
| Q2 2025 | 2025-06-30 | 3.11 | −1.17 | −27.26% |
| Q1 2025 | 2025-03-31 | 3.13 | −2.55 | −44.86% |
| Q4 2024 | 2024-12-31 | 3.20 | −1.96 | −37.98% |
| Q3 2024 | 2024-09-30 | 3.16 | −3.53 | −52.77% |
| Q2 2024 | 2024-06-30 | 4.28 | −3.14 | −42.28% |
| Q1 2024 | 2024-03-31 | 5.68 | −2.41 | −29.80% |
| Q4 2023 | 2023-12-31 | 5.17 | −2.30 | −30.84% |
| Q3 2023 | 2023-09-30 | 6.69 | −0.54 | −7.48% |
| Q2 2023 | 2023-06-30 | 7.42 | −2.32 | −23.80% |
| Q1 2023 | 2023-03-31 | 8.10 | −2.06 | −20.28% |
| Q4 2022 | 2022-12-31 | 7.47 | −1.40 | −15.75% |
| Q3 2022 | 2022-09-30 | 7.23 | −2.16 | −22.98% |
| Q2 2022 | 2022-06-30 | 9.73 | −3.16 | −24.49% |
| Q1 2022 | 2022-03-31 | 10.16 | −12.42 | −55.01% |
| Q4 2021 | 2021-12-31 | 8.87 | 6.62 | +293.92% |
| Q3 2021 | 2021-09-30 | 9.39 | — | — |
| Q2 2021 | 2021-06-30 | 12.89 | — | — |
| Q1 2021 | 2021-03-31 | 22.58 | — | — |
| Q4 2020 | 2020-12-31 | 2.25 | — | — |
Bolt Biotherapeutics current ratio trends
Over the last five fiscal years, Bolt Biotherapeutics's current ratio increased from 2.25 to 3.59, a change of 1.34. The latest reported quarter, Q2 2026, shows 2.61.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bolt Biotherapeutics source filings ↗